<DOC>
	<DOCNO>NCT02807051</DOCNO>
	<brief_summary>This open-label , single-center , crossover , one-way , drug-interaction study evaluate effect 500 mg clarithromycin BID ( dose steady state ) PK single 400-mg dose pacritinib healthy male female subject .</brief_summary>
	<brief_title>To Evaluate Effect Clarithromycin Systemic Exposure Pacritinib Healthy Subjects</brief_title>
	<detailed_description>This single-center , open-label , one-way crossover , drug-interaction study . On Day 1 , subject receive single oral 400-mg dose pacritinib . On Day 8 morning Day 12 , follow 7-day washout period , 500-mg oral dos clarithromycin administer twice daily ( BID ) , 8 12 hour apart . It anticipate steady-state concentration clarithromycin would achieve Day 12 . On Day 12 , single oral 400-mg dose pacritinib co-administered final 500-mg dose clarithromycin .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1. male female , 18 55 year age , inclusive ; 2 . BMI 18.5 32.0 kg/m2 , inclusive ; 3. good health , determine clinically significant finding medical history , physical examination , vital sign ; 4. clinical laboratory evaluation ( include clinical chemistry panel [ fast least 10 hour ] , CBC , UA ) within reference range test laboratory , unless deem clinically significant Investigator ; 5. negative test select drug abuse ( include alcohol ) Screening Checkin ; 6. negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] hepatitis C virus antibody [ antiHCV ] ) negative HIV antibody screen ; 7. female childbearing potential must nonpregnant nonlactating , agree use contraception time sign informed consent 10 day prior Checkin ( Day 1 ) 30 day final dose administration . One follow form contraception must use time sign informed consent 10 day prior Checkin ( Day 1 ) 30 day final dose administration : nonhormonal intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( eg , NuvaRing® ) ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence . Oral , implantable , transdermal , injectable hormonal contraceptive may use time sign informed consent 10 day prior Checkin ( Day 1 ) 14 day final dose administration . For female , pregnancy test result must negative Screening Checkin ( Day 1 ) . Females childbearing potential must postmenopausal least 1 year surgically sterile ( eg , tubal ligation , hysterectomy ) least 90 day ; 8. male either surgically sterile ( ie , vasectomy , document medical record physician ) agree use Checkin ( Day 1 ) 90 day follow Study Completion ( Day 19 ) /ET , one follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner IUD spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , injectable contraceptive . Subjects must agree refrain sperm donation Checkin ( Day 1 ) 90 day follow Study Completion ( Day 19 ) /ET ; 9. able comprehend willing sign Informed Consent Form ( ICF ) . 1. history clinical manifestation clinically significant cardiovascular , pulmonary , hepatic ( eg , hepatitis ) , renal , hematologic , gastrointestinal ( eg , celiac disease , peptic ulcer , gastroesophageal reflux , inflammatory bowel disease ) , metabolic , allergic , dermatological , neurological , psychiatric disorder ( determined Investigator ; appendectomy cholecystectomy consider clinically significant disease ) ; 2. abnormality liver function test ( any/all alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase &gt; 1.5 × upper limit normal [ ULN ] ; gammaglutamyl transferase &gt; 2 × ULN ; total bilirubin &gt; 1.3 × ULN ) kidney function test ( serum creatinine &gt; ULN ) consider clinically significant Investigator , consultation Sponsor ; 3. history malignancy , except follow ; cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp ; 4. history significant hypersensitivity , intolerance , allergy drug compound , food , substance , include clarithromycin , unless approve Investigator ; 5. history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy hernia repair allow ; 6. history Gilbert 's Syndrome ; 7. history presence abnormal ECG , , Investigator 's opinion , clinically significant ; QTcF &gt; 450 msec , factor increase risk QTc interval prolongation ( eg , heart failure , hypokalemia [ define serum potassium &lt; 3.0 mEq/L persistent refractory correction ] , family history long QT interval syndrome ) 8. history alcoholism drug addiction within 1 year prior Checkin ( Day 1 ) ; 9. use tobacco nicotinecontaining product within 6 month prior Checkin ( Day 1 ) entire study ; 10. consumption alcohol caffeinecontaining food beverages 72 hour prior Screening entire study ; 11. consumption grapefruitcontaining food beverage CYP3A4 inhibitor inducers 72 hour prior Screening entire study 12. participation investigational drug trial receipt investigational study drug occur within 5 halflives 30 day prior Checkin ( Day 1 ) , whichever longer ; 13. use oral , implantable , injectable , transdermal hormonal contraceptive within 10 day prior Checkin ( Day 1 ) time sign informed consent ( female ) 14 day final dose administration ; 14. use prescription medication and/or product within 14 day prior Checkin ( Day 1 ) entire study , unless deem acceptable Investigator consultation Sponsor ; 15. use overthecounter , nonprescription preparation ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin ( Day 1 ) entire study , unless deem acceptable Investigator ; 16. poor peripheral venous access ; 17. donation blood 30 day prior Screening Study Completion ( Day 19 ) /ET , inclusive , plasma 2 week prior Screening Study Completion ( Day 19 ) /ET , inclusive ; 18. receipt blood product within 2 month prior Checkin ( Day 1 ) ; 19. acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>